Cytokines, cellular & molecular therapy最新文献_第10页

Adjunctive immunotherapy of tuberculosis. 肺结核的辅助免疫治疗。

Cytokines, cellular & molecular therapy Pub Date : 1998-06-01

Z Toossi

{"title":"Adjunctive immunotherapy of tuberculosis.","authors":"Z Toossi","doi":"","DOIUrl":"","url":null,"abstract":"Tuberculosis persists as a major infectious disease contributing to significant morbidity and mortality worldwide. Presently, antituberculous chemotherapy remains the mainstay of control of tuberculosis; however, it is associated with complexities including issues of patient compliance, drug toxicity, and inadequacy to eradicate all Mycobacterium tuberculosis at sites of infection. Recent understanding of the immunopathogenesis of tuberculosis allows the possible application of adjunctive immunotherapy to the treatment of tuberculosis. Therapies that would upregulate the host antimycobacterial immune response and/or attenuate T-cell-suppressive and macrophage-deactivating cytokines may prove to be useful in the treatment of tuberculosis. T helper 1 cytokines, such as interferon gamma, IL-2, and IL-12 through enhancement of T-cell function and macrophage activation may prove to be potent immunotherapeutic agents. On the other hand, agents that inhibit deactivating cytokines (such as transforming growth factor beta) or reduce the production and effect of pro-inflammatory molecules (such as tumor necrosis factor alpha) may also prove to be useful. Other issues to consider in an immunotherapeutic approach to tuberculosis are the administration of agents locally to sites of Mycobacterium tuberculosis infection, and employing combinations of agents to modulate the cytokine milieu of the granulomas more effectively. Adjunctive immunotherapy may be particularly useful in the management of difficult-to-treat tuberculosis or tuberculosis in the immunodeficient host.","PeriodicalId":79485,"journal":{"name":"Cytokines, cellular & molecular therapy","volume":"4 2","pages":"105-12"},"PeriodicalIF":0.0,"publicationDate":"1998-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20597932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance. 儿童急性淋巴细胞白血病的残留病变:检测方法及临床相关性。

Cytokines, cellular & molecular therapy Pub Date : 1998-06-01

S Faderl, Z Estrov

{"title":"Residual disease in acute lymphoblastic leukemia of childhood: methods of detection and clinical relevance.","authors":"S Faderl, Z Estrov","doi":"","DOIUrl":"","url":null,"abstract":"Over the last three decades, acute lymphoblastic leukemia (ALL) of childhood has turned from a once fatal condition into a disease that can be cured in about two-thirds of patients. Nevertheless, about 30% of these children relapse with a dismal prognosis. Achievement of complete remission is an essential step in successful therapy. However, patients in complete remission as defined by morphologic criteria can still harbor more than 10(9) leukemic cells. We have recently shown that residual disease is detected in most patients after completion of therapy. The amount of persistent 'indolent' disease that is actually present in a particular patient and the degree to which it must be reduced to maintain a long-term remission is largely unknown. In order to address this question, and hence to tailor efficient therapy in accordance with the needs of the individual patient, a multitude of techniques for the detection of residual disease have been developed over the last few years. The most commonly used techniques are the polymerase chain reaction (PCR) assays. These sensitive assays have revolutionized this area of research. The heterogeneity of the results obtained, however, still precludes widespread clinical applicability of these techniques.","PeriodicalId":79485,"journal":{"name":"Cytokines, cellular & molecular therapy","volume":"4 2","pages":"73-85"},"PeriodicalIF":0.0,"publicationDate":"1998-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20598597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFN-gamma, or combination IL-2 + IFN-gamma. 细胞因子基因修饰的肿瘤细胞用于预防性和治疗性疫苗接种:IL-2, ifn - γ，或IL-2 + ifn - γ的组合。

Cytokines, cellular & molecular therapy Pub Date : 1998-06-01

R Kircheis, Z Küpcü, G Wallner, E Wagner

引用次数: 0

Thrombopoietin in vitro and in vivo. 体外和体内的血小板生成素。

Cytokines, cellular & molecular therapy Pub Date : 1998-03-01

W S Alexander, C G Begley

{"title":"Thrombopoietin in vitro and in vivo.","authors":"W S Alexander, C G Begley","doi":"","DOIUrl":"","url":null,"abstract":"The characterization of the c-Mpl receptor resulted from studies on a murine retrovirus, and proved an important step in the identification of a key hemopoietic regulator. First proposed and named in 1958, the ultimate characterization of the long-awaited 'thrombopoietin' (TPO) came with the molecular cloning and characterization of the in vitro and in vivo properties of the c-Mpl ligand. Gene targeting experiments have demonstrated that the TPO/Mpl receptor signalling pathway is the principal physiological regulator of megakaryocytes and platelets. Analysis of signalling through c-Mpl has provided important insights into the function of this pathway, which, as with other members of the hemopoietin receptor family, involves activation of the JAK/STAT and Ras signalling cascades. Preclinical studies have documented a role for this molecule in overcoming thrombocytopenia following chemo/radiotherapy in several animal models. Clinical studies have demonstrated the safety and efficacy of Mpl ligand in elevating platelet counts. The identification of thrombopoietin has provided an important impetus in understanding megakaryocyte and platelet physiology, and provided a new therapeutic that will find application in a variety of clinical contexts.","PeriodicalId":79485,"journal":{"name":"Cytokines, cellular & molecular therapy","volume":"4 1","pages":"25-34"},"PeriodicalIF":0.0,"publicationDate":"1998-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20478184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IL-1 receptor antagonist gene polymorphism in patients with secondary acute myeloid leukaemia. 继发性急性髓性白血病患者IL-1受体拮抗剂基因多态性的研究。

Cytokines, cellular & molecular therapy Pub Date : 1998-03-01

S E Langabeer, D C Linch

{"title":"IL-1 receptor antagonist gene polymorphism in patients with secondary acute myeloid leukaemia.","authors":"S E Langabeer, D C Linch","doi":"","DOIUrl":"","url":null,"abstract":"Acute myeloid leukaemia (AML) may not only occur as a de novo disease but may evolve from a preceding myelodysplastic syndrome (MDS) or may result from therapy for a previous malignancy. These secondary acute myeloid leukaemias (sAML) possess some common biological and clinical features of the corresponding de novo disorders. The cytokine interleukin-1 (IL-1) is known to have a role in haematopoiesis, and modulation of its action might contribute to the deregulation of proliferation seen in leukaemia. It has recently been reported that a variable number tandem repeat (VNTR) polymorphism in the IL-1 receptor antagonist (IL-1ra) gene is closely associated with the severity of many inflammatory and autoimmune diseases, and may also play a role in the pathogenesis of sAML. We sought to confirm this finding in a large group of patients classified as having sAML. We found no differences in either the genotypic or allele frequencies of the polymorphism studied when compared with those of normal controls or other haematological disorders. No differences were observed in allele frequencies between younger and older patients, or between those patients who had an antecedent myelodysplasia and those who had received prior chemotherapy or radiotherapy. We conclude that the described polymorphism in the IL-1ra gene is not associated with the development of sAML.","PeriodicalId":79485,"journal":{"name":"Cytokines, cellular & molecular therapy","volume":"4 1","pages":"7-9"},"PeriodicalIF":0.0,"publicationDate":"1998-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20479549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhibitory effect of interleukin-10 on human leukocyte interferon-alpha production by Sendai virus. 白细胞介素-10对仙台病毒产生人白细胞干扰素- α的抑制作用

Cytokines, cellular & molecular therapy Pub Date : 1998-03-01

X X Zhao, M J Liao, A Rashidbaigi

引用次数: 0

Molecular mechanisms of pancreatic beta-cell destruction in autoimmune diabetes: potential targets for preventive therapy. 自身免疫性糖尿病胰腺β细胞破坏的分子机制:预防治疗的潜在靶点。

Cytokines, cellular & molecular therapy Pub Date : 1998-03-01

H Iwahashi, N Itoh, K Yamagata, A Imagawa, H Nakajima, K Tomita, M Moriwaki, M Waguri, K Yamamoto, J Miyagawa, M Namba, T Hanafusa, Y Matsuzawa

{"title":"Molecular mechanisms of pancreatic beta-cell destruction in autoimmune diabetes: potential targets for preventive therapy.","authors":"H Iwahashi, N Itoh, K Yamagata, A Imagawa, H Nakajima, K Tomita, M Moriwaki, M Waguri, K Yamamoto, J Miyagawa, M Namba, T Hanafusa, Y Matsuzawa","doi":"","DOIUrl":"","url":null,"abstract":"Mononuclear cell infiltration into the islets of the pancreas (insulitis) is characteristic of autoimmune diabetes. T lymphocytes are the predominant subpopulation seen in insulitis, and are involved in the autoimmune process. Insulin-producing beta cells are thought to be destroyed by cytotoxic T cells, cytokines or nitric oxide, and beta-cell death occurs, at least partly, via apoptosis. Beta-cell death induced by cytokines is inhibited by Bcl-2, suggesting its potential as a tool for gene therapy. The Fas/Fas-ligand system plays a critical role in inducing insulitis and overt diabetes in nonobese diabetic (NOD) mice, a model of autoimmune diabetes. T-cell receptor gene usage in infiltrating T cells is not restricted in NOD mice, but there are some observations indicating relative restriction in human IDDM patients. Preventive strategies might be developed by focusing on these molecules involved in beta-cell destruction. The establishment of screening techniques for detecting prediabetic patients is also necessary to allow successful intervention.","PeriodicalId":79485,"journal":{"name":"Cytokines, cellular & molecular therapy","volume":"4 1","pages":"45-51"},"PeriodicalIF":0.0,"publicationDate":"1998-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20478186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects. 针对癌症的活性特异性t细胞免疫疗法:核酸、多肽、全天然蛋白、重组病毒、树突状细胞佐剂或全肿瘤细胞疫苗。原则与未来展望。

Cytokines, cellular & molecular therapy Pub Date : 1998-03-01

N Fernandez, M T Duffour, M Perricaudet, M T Lotze, T Tursz, L Zitvogel

引用次数: 0

Immunotherapy of cancer using dendritic cells. 利用树突状细胞对癌症进行免疫治疗。

Cytokines, cellular & molecular therapy Pub Date : 1998-03-01

M A Morse, H K Lyerly

引用次数: 0

Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. 自体干细胞移植后乳腺癌的异体细胞介导免疫治疗:一项临床试点研究。

Cytokines, cellular & molecular therapy Pub Date : 1998-03-01

R Or, A Ackerstein, A Nagler, J Kapelushnik, E Naparstek, S Samuel, A Amar, C Bruatbar, S Slavin

{"title":"Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study.","authors":"R Or, A Ackerstein, A Nagler, J Kapelushnik, E Naparstek, S Samuel, A Amar, C Bruatbar, S Slavin","doi":"","DOIUrl":"","url":null,"abstract":"Allogeneic cell therapy (allo-CT) is emerging as an effective treatment for patients relapsing after allogeneic bone marrow transplantation (BMT), indicating that tumor cells resisting chemoradiotherapy may still respond to immunocompetent allogeneic lymphocytes. We investigated possible graft-versus-tumor (GVT) effects in six patients with metastatic breast cancer that would be comparable to the graft-versus-leukemia (GVL) phenomenon occurring after allogeneic BMT in hematologic malignancies. The patients were cytoreduced with high-dose chemotherapy and autologous stem cell transplantation (ASCT), and were treated ambulatory with allo-CT consisting of adoptive transfer of HLA-matched donor peripheral blood lymphocytes (PBL) activated in vivo with human recombinant interleukin-2 (rIL-2). If no graft-versus-host disease (GVHD) developed, allo-CT was augmented with infusion of donor PBL, preactivated in vitro with rIL-2. Treatment was well tolerated, with low therapy-related toxicity in all patients. Two patients developed signs and symptoms compatible with GVHD grade I-II, one of whom shows no evidence of disease at more than 34 months out. In the remaining patients, progression-free survival following allo-CT ranged between 7 and 13 months. Allogeneic cell-mediated, cytokine-activated immunotherapy might be utilized for induction of GVT in metastatic breast cancer. A search for techniques to boost chimerism without severe GVHD is indicated.","PeriodicalId":79485,"journal":{"name":"Cytokines, cellular & molecular therapy","volume":"4 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"1998-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"20479548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0